BR112019018691A2 - derivados de indol como inibidores de bomba de efluxo - Google Patents
derivados de indol como inibidores de bomba de efluxo Download PDFInfo
- Publication number
- BR112019018691A2 BR112019018691A2 BR112019018691-3A BR112019018691A BR112019018691A2 BR 112019018691 A2 BR112019018691 A2 BR 112019018691A2 BR 112019018691 A BR112019018691 A BR 112019018691A BR 112019018691 A2 BR112019018691 A2 BR 112019018691A2
- Authority
- BR
- Brazil
- Prior art keywords
- alkyl
- carbocyclyl
- compound
- hydrogen
- petition
- Prior art date
Links
- 0 C[*+][C@](CCCNCl)CNC(c1cc(cc(cc2)-c(cc3)ccc3F)c2[n]1)=O Chemical compound C[*+][C@](CCCNCl)CNC(c1cc(cc(cc2)-c(cc3)ccc3F)c2[n]1)=O 0.000 description 16
- JISGOUTZGSQKKG-KRWDZBQOSA-N COc(cc1)ccc1-c1ccc(cc(C(NC[C@H](CCCN)N)=O)[nH]2)c2c1 Chemical compound COc(cc1)ccc1-c1ccc(cc(C(NC[C@H](CCCN)N)=O)[nH]2)c2c1 JISGOUTZGSQKKG-KRWDZBQOSA-N 0.000 description 2
- USWLQLQBVASTSA-SFHVURJKSA-N C[n](c(C(NC[C@H](CCCN)N)=O)c1)c2c1ccc(-c(cc1)ccc1F)c2 Chemical compound C[n](c(C(NC[C@H](CCCN)N)=O)c1)c2c1ccc(-c(cc1)ccc1F)c2 USWLQLQBVASTSA-SFHVURJKSA-N 0.000 description 2
- ZRCJAWNRQFRQKP-KRWDZBQOSA-N NCCC[C@@H](CNC(c([nH]c1c2)cc1ccc2-c(cc1)ccc1F)=O)N Chemical compound NCCC[C@@H](CNC(c([nH]c1c2)cc1ccc2-c(cc1)ccc1F)=O)N ZRCJAWNRQFRQKP-KRWDZBQOSA-N 0.000 description 2
- FPFJFOADICIPKN-UHFFFAOYSA-N CC(C)(C)OC(NCCCCCNC(c([nH]c1cc(-c(cc2)ccc2F)c2)cc1c2OC)=O)=O Chemical compound CC(C)(C)OC(NCCCCCNC(c([nH]c1cc(-c(cc2)ccc2F)c2)cc1c2OC)=O)=O FPFJFOADICIPKN-UHFFFAOYSA-N 0.000 description 1
- SGXPNRFSZZJWEZ-DEOSSOPVSA-N CC(C)(C)OC(NCCC[C@@H](CNC(Cc1c[nH]c(cc2)c1cc2-c(cc1)ccc1F)=O)NC(OC(C)(C)C)=O)=O Chemical compound CC(C)(C)OC(NCCC[C@@H](CNC(Cc1c[nH]c(cc2)c1cc2-c(cc1)ccc1F)=O)NC(OC(C)(C)C)=O)=O SGXPNRFSZZJWEZ-DEOSSOPVSA-N 0.000 description 1
- KDLGCPHQDVNPOT-SFHVURJKSA-N CC(C)(C)OC(NCCC[C@@H](CNC(Cc1c[nH]c(cc2)c1cc2Br)=O)NC(OC(C)(C)C)=O)=O Chemical compound CC(C)(C)OC(NCCC[C@@H](CNC(Cc1c[nH]c(cc2)c1cc2Br)=O)NC(OC(C)(C)C)=O)=O KDLGCPHQDVNPOT-SFHVURJKSA-N 0.000 description 1
- DILFTFXKEBNONQ-QHCPKHFHSA-N CC(C)(C)OC(NCCC[C@@H](CNC(c1cc(ccc(-c(cc2)ccc2F)c2)c2[nH]1)=O)NC(OC(C)(C)C)=O)=O Chemical compound CC(C)(C)OC(NCCC[C@@H](CNC(c1cc(ccc(-c(cc2)ccc2F)c2)c2[nH]1)=O)NC(OC(C)(C)C)=O)=O DILFTFXKEBNONQ-QHCPKHFHSA-N 0.000 description 1
- FLWGJNSGPZWACS-DEOSSOPVSA-N CC(C)(C)OC(NCCC[C@@H](CNC(c1cc(ccc(-c(cc2)ccc2F)c2)c2[n]1C)=O)NC(OC(C)(C)C)=O)=O Chemical compound CC(C)(C)OC(NCCC[C@@H](CNC(c1cc(ccc(-c(cc2)ccc2F)c2)c2[n]1C)=O)NC(OC(C)(C)C)=O)=O FLWGJNSGPZWACS-DEOSSOPVSA-N 0.000 description 1
- ARZDVRZKXBQOBS-UHFFFAOYSA-N CC(C)(C)OC(NCCNC(CCC1)CC1N)=O Chemical compound CC(C)(C)OC(NCCNC(CCC1)CC1N)=O ARZDVRZKXBQOBS-UHFFFAOYSA-N 0.000 description 1
- IKJMELVAFLIHET-INIZCTEOSA-N CC(C)(C)OC(NCC[C@@H](CN(C(c1ccccc11)=C)C1=O)NC(OC(C)(C)C)=O)=O Chemical compound CC(C)(C)OC(NCC[C@@H](CN(C(c1ccccc11)=C)C1=O)NC(OC(C)(C)C)=O)=O IKJMELVAFLIHET-INIZCTEOSA-N 0.000 description 1
- DLFPNVQGKLRHFT-AXDSSHIGSA-N CC(C)C(C)CC[C@@H](CO)NC Chemical compound CC(C)C(C)CC[C@@H](CO)NC DLFPNVQGKLRHFT-AXDSSHIGSA-N 0.000 description 1
- NIRWXOBKHSZLBP-RGURZIINSA-N CC(C)C(CC[C@@H](CNC(C)=O)N)N Chemical compound CC(C)C(CC[C@@H](CNC(C)=O)N)N NIRWXOBKHSZLBP-RGURZIINSA-N 0.000 description 1
- NHZCKVGXUAZDQJ-XJDOXCRVSA-N CC(C)C(CC[C@@H](CNC(c1cc(ccc(-c(cc2)ccc2F)c2)c2[nH]1)=O)N)N Chemical compound CC(C)C(CC[C@@H](CNC(c1cc(ccc(-c(cc2)ccc2F)c2)c2[nH]1)=O)N)N NHZCKVGXUAZDQJ-XJDOXCRVSA-N 0.000 description 1
- DRIRUQKGXOLLOS-QHCPKHFHSA-N CC(C)C(CC[C@@H](CO[Si](C(C)(C)C)(c1ccccc1)c1ccccc1)NC(OC(C)(C)C)=O)=O Chemical compound CC(C)C(CC[C@@H](CO[Si](C(C)(C)C)(c1ccccc1)c1ccccc1)NC(OC(C)(C)C)=O)=O DRIRUQKGXOLLOS-QHCPKHFHSA-N 0.000 description 1
- YGTLYBUFWCCGST-MHINKWEDSA-N CC(C1)[N]1(C(CC1)CCC1N(CC1)C[C@H]1N)C(OCc1ccccc1)=O Chemical compound CC(C1)[N]1(C(CC1)CCC1N(CC1)C[C@H]1N)C(OCc1ccccc1)=O YGTLYBUFWCCGST-MHINKWEDSA-N 0.000 description 1
- NWQKZNSGVLFRJY-LURJTMIESA-N CC(NC[C@H](CCN)N)=O Chemical compound CC(NC[C@H](CCN)N)=O NWQKZNSGVLFRJY-LURJTMIESA-N 0.000 description 1
- RCEQOBAYZNEIDY-SFYZADRCSA-N CC(NC[C@H]1NC[C@@H](CN)C1)=O Chemical compound CC(NC[C@H]1NC[C@@H](CN)C1)=O RCEQOBAYZNEIDY-SFYZADRCSA-N 0.000 description 1
- XWWWMZJWZIZBIK-DYAUCHOISA-N CC/C=C\C(C)(/C=C1/NC(C(O)=O)=C/C1=C(/C=C)\OC)F Chemical compound CC/C=C\C(C)(/C=C1/NC(C(O)=O)=C/C1=C(/C=C)\OC)F XWWWMZJWZIZBIK-DYAUCHOISA-N 0.000 description 1
- WYSLMGFLJILMSV-ZETCQYMHSA-N CCC(NC[C@H](CCCN)N)=O Chemical compound CCC(NC[C@H](CCCN)N)=O WYSLMGFLJILMSV-ZETCQYMHSA-N 0.000 description 1
- RORGQQMXCVRCTR-MLWJPKLSSA-N CCC1CN[C@H](CO)C1 Chemical compound CCC1CN[C@H](CO)C1 RORGQQMXCVRCTR-MLWJPKLSSA-N 0.000 description 1
- ASGNBQGNCHPNOA-QMMMGPOBSA-N CCCC[C@@H](CNC(C)=O)N Chemical compound CCCC[C@@H](CNC(C)=O)N ASGNBQGNCHPNOA-QMMMGPOBSA-N 0.000 description 1
- NELGYSULZPTMBF-UHFFFAOYSA-N COC(c([nH]c1c2)cc1ccc2-c(cc1)ccc1F)=O Chemical compound COC(c([nH]c1c2)cc1ccc2-c(cc1)ccc1F)=O NELGYSULZPTMBF-UHFFFAOYSA-N 0.000 description 1
- STNWFORTTQFNRG-UHFFFAOYSA-N COC(c1cc(c(OC)cc(-c(cc2)ccc2F)c2)c2[nH]1)=O Chemical compound COC(c1cc(c(OC)cc(-c(cc2)ccc2F)c2)c2[nH]1)=O STNWFORTTQFNRG-UHFFFAOYSA-N 0.000 description 1
- BYKIOJVEURZQTB-UHFFFAOYSA-N COC(c1cc(c(OC)cc(Br)c2)c2[nH]1)=O Chemical compound COC(c1cc(c(OC)cc(Br)c2)c2[nH]1)=O BYKIOJVEURZQTB-UHFFFAOYSA-N 0.000 description 1
- HIRNDAVWLKNFFZ-QGZVFWFLSA-N COc1c(cc(C(NC[C@@H](CCCN)[N]#C)=O)[nH]2)c2cc(-c(cc2)ccc2F)c1 Chemical compound COc1c(cc(C(NC[C@@H](CCCN)[N]#C)=O)[nH]2)c2cc(-c(cc2)ccc2F)c1 HIRNDAVWLKNFFZ-QGZVFWFLSA-N 0.000 description 1
- ULAKQXVWRWBVQO-KRWDZBQOSA-N Cc1c(C(NC[C@H](CCCN)N)=O)[nH]c(cc2)c1cc2-c(cc1)ccc1F Chemical compound Cc1c(C(NC[C@H](CCCN)N)=O)[nH]c(cc2)c1cc2-c(cc1)ccc1F ULAKQXVWRWBVQO-KRWDZBQOSA-N 0.000 description 1
- YILSVXBRJVOBLR-UHFFFAOYSA-N Cc1c(C(O)=O)[nH]c(cc2)c1cc2-c(cc1)ccc1F Chemical compound Cc1c(C(O)=O)[nH]c(cc2)c1cc2-c(cc1)ccc1F YILSVXBRJVOBLR-UHFFFAOYSA-N 0.000 description 1
- GEQHKFFSPGPGLN-UHFFFAOYSA-N NC(CCC1)CC1N Chemical compound NC(CCC1)CC1N GEQHKFFSPGPGLN-UHFFFAOYSA-N 0.000 description 1
- ZCYAUYHYNCDOCK-SFHVURJKSA-N NCCC[C@@H](CNC(Cc1c[nH]c(cc2)c1cc2-c(cc1)ccc1F)=O)N Chemical compound NCCC[C@@H](CNC(Cc1c[nH]c(cc2)c1cc2-c(cc1)ccc1F)=O)N ZCYAUYHYNCDOCK-SFHVURJKSA-N 0.000 description 1
- GZUGFQSOSDPRRI-DEOSSOPVSA-N NCCC[C@@H](CNC(c([n](Cc(cc1)ccc1F)c1c2)cc1ccc2-c(cc1)ccc1F)=O)N Chemical compound NCCC[C@@H](CNC(c([n](Cc(cc1)ccc1F)c1c2)cc1ccc2-c(cc1)ccc1F)=O)N GZUGFQSOSDPRRI-DEOSSOPVSA-N 0.000 description 1
- IMVVSWAHFLQPEP-INIZCTEOSA-N NCCC[C@@H](CNC(c1cc(ccc(-c(cc2)ccc2[N+]([O-])=O)c2)c2[nH]1)=O)N Chemical compound NCCC[C@@H](CNC(c1cc(ccc(-c(cc2)ccc2[N+]([O-])=O)c2)c2[nH]1)=O)N IMVVSWAHFLQPEP-INIZCTEOSA-N 0.000 description 1
- SYLXMRLSBYVMKL-NQCNTLBGSA-N N[C@@H](CCC(C1CC1)N)CNC(c1cc(ccc(-c2ccc(C3CC3)cc2)c2)c2[nH]1)=O Chemical compound N[C@@H](CCC(C1CC1)N)CNC(c1cc(ccc(-c2ccc(C3CC3)cc2)c2)c2[nH]1)=O SYLXMRLSBYVMKL-NQCNTLBGSA-N 0.000 description 1
- YIMDEMGBMNRVFD-UHFFFAOYSA-N O=C(c1cc(ccc(-c(cc2)ccc2F)c2)c2[nH]1)NCCNC1CCNCC1 Chemical compound O=C(c1cc(ccc(-c(cc2)ccc2F)c2)c2[nH]1)NCCNC1CCNCC1 YIMDEMGBMNRVFD-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762469987P | 2017-03-10 | 2017-03-10 | |
| US62/469,987 | 2017-03-10 | ||
| US201762523154P | 2017-06-21 | 2017-06-21 | |
| US62/523,154 | 2017-06-21 | ||
| PCT/US2018/021848 WO2018165611A1 (en) | 2017-03-10 | 2018-03-09 | Indole derivatives as efflux pump inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019018691A2 true BR112019018691A2 (pt) | 2020-04-07 |
Family
ID=62044950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019018691-3A BR112019018691A2 (pt) | 2017-03-10 | 2018-03-09 | derivados de indol como inibidores de bomba de efluxo |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11993571B2 (https=) |
| EP (1) | EP3592736A1 (https=) |
| JP (1) | JP7323179B2 (https=) |
| KR (1) | KR102697360B1 (https=) |
| CN (1) | CN110770224B (https=) |
| AU (1) | AU2018231120B2 (https=) |
| BR (1) | BR112019018691A2 (https=) |
| CA (1) | CA3061238A1 (https=) |
| IL (1) | IL269210B2 (https=) |
| MX (1) | MX2019010717A (https=) |
| SG (1) | SG11201908351TA (https=) |
| WO (1) | WO2018165611A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10556854B2 (en) | 2016-02-24 | 2020-02-11 | Rutgers, The State University Of New Jersey | Bacterial efflux pump inhibitors |
| WO2017147335A1 (en) | 2016-02-24 | 2017-08-31 | Rutgers, The State University Of New Jersey | Bacterial efflux pump inhibitors |
| SG11201908351TA (en) | 2017-03-10 | 2019-10-30 | Edmond J Lavoie | Indole derivatives as efflux pump inhibitors |
| US11938114B2 (en) | 2017-03-10 | 2024-03-26 | Rutgers, The State University Of New Jersey | Bacterial efflux pump inhibitors |
| WO2018165612A1 (en) | 2017-03-10 | 2018-09-13 | Rutgers, The State University Of New Jersey | Bacterial efflux pump inhibitors |
| EP3630109A4 (en) | 2017-05-26 | 2021-03-17 | Rutgers, the State University of New Jersey | BACTERIAL EFFLUX PUMP INHIBITORS |
| WO2019005841A1 (en) | 2017-06-26 | 2019-01-03 | Rutgers, The State University Of New Jersey | THERAPEUTIC COMPOUNDS AND METHODS FOR TREATING INFECTION |
| WO2019099402A1 (en) * | 2017-11-14 | 2019-05-23 | Rutgers, The State University Of New Jersey | Therapeutic compounds and methods to treat infection |
| KR102704123B1 (ko) | 2019-11-01 | 2024-09-06 | 에스엘 주식회사 | 차량용 램프 |
| WO2025043115A1 (en) | 2023-08-23 | 2025-02-27 | Taxis Pharmaceuticals, Inc. | Bacterial efflux pump inhibitors |
| AU2024332661A1 (en) * | 2023-08-29 | 2026-04-09 | Maze Therapeutics, Inc. | Inhibitors of solute carrier family 6a member 19 (slc6a19) and methods of use thereof |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3238215A (en) * | 1963-10-17 | 1966-03-01 | Sterling Drug Inc | 1-[(3-, 2-, and 1-indolyl)-lower-alkyl-, lower-alkenyl-, and lower-alkynyl]piperidines |
| US3465080A (en) * | 1968-10-07 | 1969-09-02 | American Cyanamid Co | Therapeutic compositions containing morpholinoalkylene - indoles and methods of administering such in the treatment of depression |
| US3978224A (en) | 1975-07-01 | 1976-08-31 | Schering Corporation | Antimicrobial halo-substituted-2-cyanoethylaminoalkyl-3-phenyl-indoles |
| US4910193A (en) * | 1985-12-16 | 1990-03-20 | Sandoz Ltd. | Treatment of gastrointestinal disorders |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| WO1992004017A1 (en) | 1990-09-10 | 1992-03-19 | The Upjohn Company | Cis-n-(2-aminocyclohexyl)benzamide and their enantiomers as anticonvulsants |
| US5864039A (en) * | 1994-03-30 | 1999-01-26 | Yoshitomi Pharmaceutical Industries, Ltd. | Benzoic acid compounds and use thereof as medicaments |
| US5663152A (en) | 1995-01-19 | 1997-09-02 | Asahi Kasei Kogyo Kabushiki Kaisha | Potentiators for aminoglycosides |
| US6506339B1 (en) * | 1997-02-10 | 2003-01-14 | Biomedical Design, Inc. | Method of sterilization |
| WO1999037667A1 (en) * | 1998-01-23 | 1999-07-29 | Microcide Pharmaceuticals, Inc. | Efflux pump inhibitors |
| US6204279B1 (en) | 1998-06-03 | 2001-03-20 | Microcide Pharmaceuticals, Inc. | Peptidomimetic efflux pump inhibitors |
| US6326391B1 (en) | 1998-12-04 | 2001-12-04 | Influx, Inc. | Inhibitors of multidrug transporters |
| US6730684B1 (en) * | 1999-10-08 | 2004-05-04 | Affinium Pharmaceuticals, Inc. | Fab I inhibitors |
| WO2001026652A1 (en) | 1999-10-08 | 2001-04-19 | Smithkline Beecham Corporation | Fab i inhibitors |
| US6555569B2 (en) | 2000-03-07 | 2003-04-29 | Pfizer Inc. | Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection |
| WO2011101710A1 (en) | 2010-02-16 | 2011-08-25 | Wockhardt Research Centre | Efflux pump inhibitors |
| WO2003000657A1 (en) | 2001-06-20 | 2003-01-03 | Daiichi Pharmaceutical Co., Ltd. | Diamine derivatives |
| HUP0103986A2 (hu) * | 2001-09-28 | 2003-06-28 | Richter Gedeon Vegyészeti Gyár Rt. | Új karbonsavamid szerkezetet tartalmazó piperidinil vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények |
| EP1314733A1 (en) * | 2001-11-22 | 2003-05-28 | Aventis Pharma Deutschland GmbH | Indole-2-carboxamides as factor Xa inhibitors |
| WO2004062674A2 (en) | 2003-01-07 | 2004-07-29 | Paratek Pharmaceuticals, Inc. | Substituted polyamines as inhibitors of bacterial efflux pumps |
| GB0403038D0 (en) * | 2004-02-11 | 2004-03-17 | Novartis Ag | Organic compounds |
| US7994225B2 (en) | 2004-03-17 | 2011-08-09 | Rempex Pharmaceuticals, Inc. | Bacterial efflux pump inhibitors for the treatment of ophthalmic and otic infections |
| EP1758920A1 (en) | 2004-05-21 | 2007-03-07 | Mpex Pharmaceuticals, Inc. | Bacterial efflux pump inhibitors and methods of treating bacterial infections |
| WO2006058088A2 (en) | 2004-11-23 | 2006-06-01 | Ptc Therapeutics, Inc. | Carbazole, carboline and indole derivatives useful in the inhibition of vegf production |
| US7855228B2 (en) | 2005-02-10 | 2010-12-21 | The Board Of Trustees Of The Leland Stamford Junior University | Antibiotics targeting MreB |
| WO2007115231A2 (en) * | 2006-03-30 | 2007-10-11 | Chemocentryx, Inc. | Cxcr4 modulators |
| FR2904317A1 (fr) * | 2006-07-27 | 2008-02-01 | Inst Nat Sante Rech Med | Analogues d'halogenobenzamides marques a titre de radiopharmaceutiques |
| CA2927045A1 (en) | 2006-10-03 | 2008-04-10 | Muthiah Manoharan | Lipid containing formulations |
| AR070398A1 (es) * | 2008-02-22 | 2010-03-31 | Gruenenthal Chemie | Derivados sustituidos de indol |
| WO2009110002A1 (en) | 2008-03-05 | 2009-09-11 | Council Of Scientific & Industrial Research | Novel efflux pump inhibitors |
| JP5608655B2 (ja) | 2008-09-18 | 2014-10-15 | エヴォテック アーゲー | Ｐ２ｘ３受容体活性のモジュレーター |
| WO2010115184A2 (en) | 2009-04-03 | 2010-10-07 | Achillion Pharmaceuticals, Inc. | Hydroxythienoquinolones and related compounds as anti-infective agents |
| EP2394653A1 (en) * | 2010-05-26 | 2011-12-14 | Almirall, S.A. | Topical pharmaceutical compositions comprising mometasone furoate |
| FR2969150B1 (fr) * | 2010-12-20 | 2013-07-26 | Centre Nat Rech Scient | Nouvelles molecules indoliques demontrant des activites antibacteriennes dans une variete de bacteries a gram-negatif et positif dont des bacteries multidrogues-resistantes |
| ES2660210T3 (es) | 2012-09-07 | 2018-03-21 | Novartis Ag | Derivados de indolcarboxamida y usos de los mismos |
| WO2014078294A1 (en) * | 2012-11-13 | 2014-05-22 | Memorial Sloan-Kettering Cancer Center | Indole compounds and their use as antimicrobials |
| WO2015164482A1 (en) * | 2014-04-22 | 2015-10-29 | The Johns Hopkins University | Inhibitors of drug-resistant mycobacterium tuberculosis |
| BR112017004612A2 (pt) | 2014-09-10 | 2018-01-30 | Epizyme, Inc. | compostos, composição farmacêutica, usos de um composto, e kit |
| US9926261B2 (en) | 2015-03-10 | 2018-03-27 | Rutgers, The State University Of New Jersey | Bacterial efflux pump inhibitors |
| US9950993B2 (en) | 2015-03-13 | 2018-04-24 | Rutgers, The State University Of New Jersey | Bacterial efflux pump inhibitors |
| CN107709314A (zh) | 2015-06-11 | 2018-02-16 | 巴斯利尔药物国际股份公司 | 外排泵抑制剂及其治疗性用途 |
| WO2017023894A1 (en) * | 2015-08-03 | 2017-02-09 | Raze Therapeutics, Inc. | Mthfd2 inhibitors and uses thereof |
| WO2017147335A1 (en) | 2016-02-24 | 2017-08-31 | Rutgers, The State University Of New Jersey | Bacterial efflux pump inhibitors |
| US10556854B2 (en) | 2016-02-24 | 2020-02-11 | Rutgers, The State University Of New Jersey | Bacterial efflux pump inhibitors |
| CA3047404A1 (en) | 2016-12-23 | 2018-06-28 | Aquinnah Pharmaceuticals, Inc. | Compounds, compositions and methods of use |
| SG11201908351TA (en) | 2017-03-10 | 2019-10-30 | Edmond J Lavoie | Indole derivatives as efflux pump inhibitors |
| US11938114B2 (en) | 2017-03-10 | 2024-03-26 | Rutgers, The State University Of New Jersey | Bacterial efflux pump inhibitors |
| WO2018165612A1 (en) | 2017-03-10 | 2018-09-13 | Rutgers, The State University Of New Jersey | Bacterial efflux pump inhibitors |
| EP3630109A4 (en) | 2017-05-26 | 2021-03-17 | Rutgers, the State University of New Jersey | BACTERIAL EFFLUX PUMP INHIBITORS |
| WO2019005841A1 (en) | 2017-06-26 | 2019-01-03 | Rutgers, The State University Of New Jersey | THERAPEUTIC COMPOUNDS AND METHODS FOR TREATING INFECTION |
| US20190031624A1 (en) | 2017-07-28 | 2019-01-31 | Rutgers, The State University Of New Jersey | Therapeutic compounds and methods to treat infection |
| WO2019099402A1 (en) * | 2017-11-14 | 2019-05-23 | Rutgers, The State University Of New Jersey | Therapeutic compounds and methods to treat infection |
-
2018
- 2018-03-09 SG SG11201908351T patent/SG11201908351TA/en unknown
- 2018-03-09 KR KR1020197029528A patent/KR102697360B1/ko active Active
- 2018-03-09 BR BR112019018691-3A patent/BR112019018691A2/pt active Search and Examination
- 2018-03-09 EP EP18719686.0A patent/EP3592736A1/en active Pending
- 2018-03-09 CA CA3061238A patent/CA3061238A1/en active Pending
- 2018-03-09 MX MX2019010717A patent/MX2019010717A/es unknown
- 2018-03-09 WO PCT/US2018/021848 patent/WO2018165611A1/en not_active Ceased
- 2018-03-09 CN CN201880030845.1A patent/CN110770224B/zh active Active
- 2018-03-09 IL IL269210A patent/IL269210B2/en unknown
- 2018-03-09 JP JP2019549454A patent/JP7323179B2/ja active Active
- 2018-03-09 US US16/492,901 patent/US11993571B2/en active Active
- 2018-03-09 AU AU2018231120A patent/AU2018231120B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190138790A (ko) | 2019-12-16 |
| KR102697360B1 (ko) | 2024-08-20 |
| CA3061238A1 (en) | 2018-09-13 |
| JP2020510044A (ja) | 2020-04-02 |
| IL269210B1 (en) | 2025-01-01 |
| CN110770224A (zh) | 2020-02-07 |
| IL269210B2 (en) | 2025-05-01 |
| MX2019010717A (es) | 2019-12-05 |
| US11993571B2 (en) | 2024-05-28 |
| EP3592736A1 (en) | 2020-01-15 |
| AU2018231120B2 (en) | 2022-06-23 |
| JP7323179B2 (ja) | 2023-08-08 |
| WO2018165611A1 (en) | 2018-09-13 |
| IL269210A (en) | 2019-11-28 |
| SG11201908351TA (en) | 2019-10-30 |
| US20210094912A1 (en) | 2021-04-01 |
| CN110770224B (zh) | 2022-11-18 |
| AU2018231120A1 (en) | 2019-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019018691A2 (pt) | derivados de indol como inibidores de bomba de efluxo | |
| AU2017265100B2 (en) | Therapeutically active compounds and their methods of use | |
| TWI833773B (zh) | 化合物 | |
| JP7281822B2 (ja) | 細菌の排出ポンプ阻害剤 | |
| CN110770242B (zh) | 作为vanin抑制剂的杂芳族化合物 | |
| TW202039435A (zh) | 經取代之3-((3-胺基苯基)胺基)哌啶-2,6-二酮化合物、其組合物及使用彼等之治療方法 | |
| KR20140040774A (ko) | 이미다조피리딘 화합물 | |
| AU2015290007B2 (en) | Fused quinoline compunds as pi3k, mTor inhibitors | |
| US20170342051A1 (en) | Indole and pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them | |
| WO2018165614A1 (en) | Bacterial efflux pump inhibitors | |
| BR112014002958B1 (pt) | 3,4-dihidro-1h-[1,8]naftiridinonas substituídas com piperidinila antibacterianas, composição farmacêutica compreendendo os referidos compostos, processos para preparação destes e uso | |
| BR112021012186A2 (pt) | Compostos de 3-((3-aminofenil)amino)piperidina-2,6-diona substituídos, composições dos mesmos e métodos de tratamento com os mesmos | |
| WO2018165612A1 (en) | Bacterial efflux pump inhibitors | |
| BR112014003146B1 (pt) | 3,4-dihidro-1h-[1,8]naftiridinonas substituídas com homopiperidinila antibacterianas, composição farmacêutica compreendendo os referidos composto e processos para preparação destes | |
| EA015123B1 (ru) | ПРОИЗВОДНЫЕ ПИРАЗОЛИЗОХИНОЛИНМОЧЕВИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ p38 КИНАЗЫ | |
| CN103848814B (zh) | 作为酪氨酸激酶抑制剂的取代吲哚满酮衍生物 | |
| JP2019520411A (ja) | トリプトファン２，３−ジオキシゲナーゼの阻害剤 | |
| TWI896831B (zh) | 一種作為ｐａｋ４激酶抑制劑的化合物及其製備方法和應用 | |
| EA034084B1 (ru) | Пан-геномные ингибиторы белка ns5a вируса гепатита с, фармацевтические композиции, промежуточные продукты для синтеза ингибиторов и способы их получения и применения | |
| HK40072575A (en) | Pharmaceutical composition useful in inhibiting idh1 | |
| HK40005387B (en) | Methods of preparing new idh1 inhibitors | |
| HK40005387A (en) | Methods of preparing new idh1 inhibitors | |
| HK40028701A (en) | Bacterial efflux pump inhibitors | |
| HK1198439B (en) | Lactam derivates useful as inhibitors of mutant idh1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS. |
|
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] |